TMCnet News
Global Genes Announces Formation of Medical Scientific Advisory Board-Adds New Members to Board of DirectorsALISO VIEJO, Calif. --(Business Wire)-- Global Genes™ announced today the formation of an inaugural leadership team, the Medical and Science Advisory Board, as well as the addition of three new members to their board of directors. "As Global Genes evolves and expands our strategic influence and reach, we are very excited to be adding insightful leadership to both our board of directors and a new multidisciplinary team of scientific and clinical thought leaders," said Nicole Boice, Global Genes Founder & CEO. "With the formation of the Medical Scientific Advisory Board, Global Genes will have the resources needed to accelerate our innovation efforts in technology, science, advocacy and research, and achieve our mission to eliminate the challenges of rare disease." New strategic talent being added to the board of directors for Global Genes includes:
The Medical & Scientific Advisory Board (MSAB) will provide strategic input, insight and expertise to the organization in the key areas of rare disease diagnostics, technology, drug development and potential partnerships related to rare disease science. The MSAB mission, goals and advisory role will be strategically aligned with the Global Genes mission 'To Eliminate the Challenges of Rare Disease.' This multidisciplinary board will serve in an advisory capacity to the Global Genes executive leadership team and will convene quarterly to further specific initiatives and work together to broaden the impact of Global Genes by advancing innovation in technology, science, advocacy and research. The MSAB consists of MDs, PhDs, MBAs, clinicians, geneticists, scientific researchers and professors. This expert team includes: >
Beth Anne Baber, PhD, MBA, Chairman and Chief Executive Officer, The Nicholas Conor Institute Hudson Freeze, MD, PhD, Professor and Director, Human Genetics Program Sanford Children's Health Research Center Sanford--Burnham Medical Research Institute Deb Geraghty, PhD, MBA, Board of Trustees, Emma Willard School, Consultant Peter Goodhand, Executive Director, Global Alliance for Genomics and Health Stephen C. Groft, PharmD, Senior Advisor to the Director, National Center for Advancing Translational Sciences (NCATs) National Institutes of Health Ayesha N. Khalid, MD, MBA, Clinical Instructor, Harvard Medical School, MIT I Sloan School of Management Harry Leider, MD, MBA, FACPE, Chief Medical Officer, Walgreens C. Jimmy Lin, MD, PhD, MHS, President, Rare Genomics Institute Jeanette McCarthy, MPH, PhD, Adjunct Associate Professor, Duke University, Visiting Associate Professor UCSF, Editor-In-Chief, Genome Magazine Sharon Moalem, MD, PhD, Chief Executive Officer, Recognyz Systems Technology David Nielsen, MD, Chief Executive Officer and Executive Vice President, American Academy of Otolaryngology-Head and Neck Surgery Ethan Perlstein, PhD, Founder Perlstein Lab, PBC Anthony Philippakis, MD, PhD, Cardiologist, Brigham and Women's Hospital, Research Scientist, Broad Institute of MIT and Harvard, Venture Partner, Google (News - Alert) Ventures Ian Phillips, PhD, DSc, Center for Rare Disease Therapies, Professor, Keck Graduate Institute Inderpal S. Randhawa, MD, Assistant Professor of Clinical Pediatrics, UC Irvine School of Medicine, Assistant Professor of Medicine, UCLA School of Medicine, Miller Children's Hospital at Long Beach Memorial Katherine Rauen, MD, MS, PhD, Professor and Medical Geneticist, University of California, Davis "RASophathies" Researcher, Presidential Early Career Awardee for Scientists and Engineers Christian Rubio, MBA, Community Director, SERMO Ryan Taft, PhD, Director of Scientific Research, Illumina, Inc. Christina Waters, PhD, MBA, Chief Executive Officer, RARE Science Keith Vaux, MD, PhD, Clinical Chief and Division Director, Medical Genetics, University of California, San Diego School of Medicine For more information on the Medical and Scientific Advisory Board, please visit www.globalgenes.org/msab/. About Global Genes - Allies in Rare Disease Global Genes™ is a leading rare disease patient advocacy organization. The group's mission is to eliminate the challenges of rare disease, by providing patients with educational tools, building awareness, providing critical connections to people and resources, and through investment in technologies that will positively impact affected patients and families. Recognized worldwide by the Blue Denim Genes Ribbon™, Global Genes unites experts, advocates and patients of all ages to stand together in hope for treatments and cures for the estimated 7,000 rare and genetic diseases that impact approximately 30 million Americans and over 350 million people worldwide.
Follow Global Genes on Facebook (News - Alert) at facebook.com/globalgenes
|